TAG:
cpt code
New Business Helps Reduce Pathology Specimen ID Errors
By Joseph Burns | From the Volume XIX No. 17 – December 10, 2012 Issue
CEO SUMMARY: Prevention of diagnostic testing errors is getting more attention by both physicians and pathology labs because patients are less tolerant of potentially life-changing errors. Strand Diagnostics’ Know Error system is designed to reduce or eliminate errors involving tissue s…
Of 88305-TC and Other Bad News for Pathology Labs
By R. Lewis Dark | From the Volume XIX No. 16 – November 19, 2012 Issue
BY NOW, VIRTUALLY ALL PATHOLOGISTS ARE AWARE of the announced cut in Medicare reimbursement for the technical component (TC) of CPT 88305. Effective on January 1, 2012, Medicare will pay 52% less for this CPT code. From the prior level of $69.78, the new reimbursement will be $33.70. As news of this…
OURLab Founder Lays Out New Business Strategy
By Joseph Burns | From the Volume XIX No. 16 – November 19, 2012 Issue
CEO SUMMARY: For OURLabs of Nashville, Tennessee, it was the host of changes in the lab testing marketplace that motivated it to go looking for a partner. Its recently-announced merger with OPKO Health, Inc., of Miami, Florida, creates opportunities for OURLab pathologists to do more in t…
Labs Have Questions about Prostate Biopsy Policy
By Joseph Burns | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: How will pathology laboratories respond to the publication of revised policies in how laboratories should file Medicare Part B claims for prostate biopsies? Not only will there be a sharp drop in the reimbursement paid for a 12-core prostate biopsy, but labs may be at increas…
Lawyer Advises on Risk Of Prostate Biopsy Audits
By Joseph Burns | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: For labs currently processing prostate biopsy cases with five or more cores and for those pathologists interpreting those cases, there is a lack of clarity about new Medicare policies. As one example, risk of an audit is significant because of recent guidance issued by one Me…
Prostate Biopsy Claims Affected by Policy Change
By Joseph Burns | From the Volume XIX No. 12 – August 27, 2012 Issue
CEO SUMMARY: Quietly, with no fanfare and little advance public notice, the Medicare program is taking steps to change reimbursement policy for prostate biopsies. On August 7, 2012, Palmetto GBA adopted the new policy published on January 1, 2012, by the National Correct …
Health Insurers Now Finding Ways to Cut Costs and Shed Risks
By Robert Michel | From the Volume XIX No. 8 – June 4, 2012 Issue
CEO SUMMARY: Both employers and health insurers are taking aggressive steps to rein in healthcare costs. Several strategies to control spending and create powerful new incentives for providers are gaining favor. At this year’s Executive War College, Paul Mango of McKinsey & Company,…
2011’s Top 10 Lab Stories Point to a Busy 2012
By Robert Michel | From the Volume XIX No. 1 – January 9, 2012 Issue
CEO SUMMARY: Given the specific news stories that make up THE DARK REPORT’S list of the “Top Ten Lab Stories for 2011,” it might be said that 2011 was a rather quiet year overshadowed by anticipation of the coming reforms mandated by the Accountable Care Act of 2010. For the clinica…
ACLA Has its Say Regarding Molecular Dx Proposals
By Robert Michel | From the Volume XVIII No. 17 – December 19, 2011 Issue
CEO SUMMARY: It is not known how many public comments have been submitted to Palmetto GBA, the big Medicare carrier, in response to its published proposals to change how code stacked claims for genetic and molecular tests will be handled, effective February 27, 2012, for labs in Medicare …
Molecular Code Stacks Now in the Payers’ Bull’s Eye
By R. Lewis Dark | From the Volume XVIII No. 16 – November 28, 2011 Issue
LIKE A STEAM BOILER READY TO EXPLODE FROM TOO MUCH PRESSURE, the nation’s health insurers have reached a point of no return on the subject of code-stacked claims for genetic testing and molecular diagnostics assays. Simply put, payers are ready to tackle this sensitive issue. Payers have reasonabl…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized